ReviewCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne1999
Drug interactions and the statins.
Review in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 87 citations in OpenAlex.
- Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.European journal of clinical pharmacology · 2005Trial
- Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions.British journal of clinical pharmacology · 2018Review
- Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians.International journal of endocrinology and metabolism · 2017Review
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.International journal of molecular sciences · 2017Review
- Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination.Case reports in medicine · 2016Article
- Potential drug interactions with statins: Estonian register-based study.Open medicine (Warsaw, Poland) · 2015Article
- Effects of statins on skeletal muscle: a perspective for physical therapists.Physical therapy · 2010Review
- Computing with evidence Part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment.Journal of biomedical informatics · 2009Article
- Statin therapy inhibits remyelination in the central nervous system.The American journal of pathology · 2009Article
- Formulary conversion programs: the need for patient-specific risk assessment.MedGenMed : Medscape general medicine · 2004Article
- Combination lipid-lowering therapy in diabetes.Current diabetes reports · 2003Review
- Common problems in the management of hypertriglyceridemia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002Article
- Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.Clinical pharmacokinetics · 2002Review
- A general assessment of the safety of HMG CoA reductase inhibitors (statins).Current atherosclerosis reports · 2002Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug interactions commonly occur in patients receiving treatment with multiple medications. Most interactions remain unrecognized because drugs, in general, have a wide margin of safety or because the extent of change in drug levels is small when compared with the variation normally seen in clinical therapy. All drug interactions have a pharmacokinetic or pharmacodynamic basis and are predictable given an understanding of the pharmacology of the drugs involved. Drugs most liable to pose problems are those having concentration-dependent toxicity within, or close to, the therapeutic range; those with steep dose-response curves; those having high first-pass metabolism or those with a single, inhibitable route of elimination. Knowing which drugs possess these intrinsic characteristics, together with a knowledge of hepatic P-450 metabolism and common enzyme-inducing and enzyme-inhibiting drugs, can greatly assist physicians in predicting interactions that may be clinically relevant. This article reviews the pharmacology of drug interactions that can occur with hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) to illustrate the scope of the problem and the ways in which physicians may manage this important therapeutic class of drugs.
Indexed as
Identifiers
10584091PMC1230792W2121055372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.